WallStreetZenWallStreetZen

NASDAQ: PHAR
Pharming Group Nv Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for PHAR

Based on 1 analyst offering 12 month price targets for Pharming Group Nv.
Min Forecast
$37.00+422.6%
Avg Forecast
$37.00+422.6%
Max Forecast
$37.00+422.6%

Should I buy or sell PHAR stock?

Based on 1 analyst offering ratings for Pharming Group Nv.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PHAR stock forecasts and price targets.

PHAR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-01

1 of 1

Forecast return on equity

Is PHAR forecast to generate an efficient return?
Company
271.17%
Industry
-388.9%
Market
58.96%
PHAR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PHAR forecast to generate an efficient return on assets?
Company
144.04%
Industry
27.36%
PHAR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PHAR earnings per share forecast

What is PHAR's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.15
Avg 2 year Forecast
$0.13
Avg 3 year Forecast
$0.58

PHAR revenue forecast

What is PHAR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$290.4M-2.71%
Avg 2 year Forecast
$331.7M+11.14%
Avg 3 year Forecast
$394.5M+32.2%
PHAR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PHAR revenue growth forecast

How is PHAR forecast to perform vs Biotechnology companies and vs the US market?
Company
9.02%
Industry
34.96%
Market
9.31%
PHAR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PHAR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PHAR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PHAR$7.08$37.00+422.60%Buy
VALN$7.00$21.50+207.14%Strong Buy
VERV$5.60$26.00+364.70%Strong Buy
ALEC$4.85$35.00+621.65%Buy
OABI$3.97$9.00+126.70%Strong Buy
View Top Biotech Stocks

Pharming Group Nv Stock Forecast FAQ

Is Pharming Group Nv Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PHAR) stock is to Buy PHAR stock.

Out of 1 analyst, 0 (0%) are recommending PHAR as a Strong Buy, 1 (100%) are recommending PHAR as a Buy, 0 (0%) are recommending PHAR as a Hold, 0 (0%) are recommending PHAR as a Sell, and 0 (0%) are recommending PHAR as a Strong Sell.

If you're new to stock investing, here's how to buy Pharming Group Nv stock.

What is PHAR's earnings growth forecast for 2024-2026?

(NASDAQ: PHAR) Pharming Group Nv's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Pharming Group Nv's earnings in 2024 is -$14,483,695.On average, 2 Wall Street analysts forecast PHAR's earnings for 2024 to be -$101,753,149, with the lowest PHAR earnings forecast at -$203,506,298, and the highest PHAR earnings forecast at $0. On average, 2 Wall Street analysts forecast PHAR's earnings for 2025 to be $84,794,291, with the lowest PHAR earnings forecast at -$271,341,730, and the highest PHAR earnings forecast at $440,930,311.

In 2026, PHAR is forecast to generate $390,053,737 in earnings, with the lowest earnings forecast at -$135,670,865 and the highest earnings forecast at $915,778,339.

What is PHAR's revenue growth forecast for 2024-2026?

(NASDAQ: PHAR) Pharming Group Nv's forecast annual revenue growth rate of 9.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Pharming Group Nv's revenue in 2024 is $301,692,391.On average, 2 Wall Street analysts forecast PHAR's revenue for 2024 to be $196,970,353,579, with the lowest PHAR revenue forecast at $192,449,122,003, and the highest PHAR revenue forecast at $201,491,585,155. On average, 2 Wall Street analysts forecast PHAR's revenue for 2025 to be $225,010,129,603, with the lowest PHAR revenue forecast at $219,515,459,570, and the highest PHAR revenue forecast at $230,504,799,635.

In 2026, PHAR is forecast to generate $267,634,523,614 in revenue, with the lowest revenue forecast at $256,601,090,518 and the highest revenue forecast at $278,667,956,710.

What is PHAR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: PHAR) forecast ROA is 144.04%, which is higher than the forecast US Biotechnology industry average of 27.36%.

What is PHAR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PHAR price target, the average PHAR price target is $37.00, with the highest PHAR stock price forecast at $37.00 and the lowest PHAR stock price forecast at $37.00.

The Wall Street analyst predicted that Pharming Group Nv's share price could reach $37.00 by Aug 1, 2025. The average Pharming Group Nv stock price prediction forecasts a potential upside of 422.6% from the current PHAR share price of $7.08.

What is PHAR's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: PHAR) Pharming Group Nv's current Earnings Per Share (EPS) is -$0.21. On average, analysts forecast that PHAR's EPS will be -$0.15 for 2024, with the lowest EPS forecast at -$0.30, and the highest EPS forecast at $0.00. On average, analysts forecast that PHAR's EPS will be $0.13 for 2025, with the lowest EPS forecast at -$0.40, and the highest EPS forecast at $0.65. In 2026, PHAR's EPS is forecast to hit $0.58 (min: -$0.20, max: $1.35).

What is PHAR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: PHAR) forecast ROE is 271.17%, which is considered strong.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.